Erschienen in:
08.08.2015 | Original Article
Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission
verfasst von:
Zhanshan Cha, Chen Li, Yan Zang, Haihui Gu, Huijun Guo, Jinqi Li, Yuan Fang, Thomas F. Petersen, Jing Li, Richard O. Karas, Michele L. Hamilton, Baohua Qian
Erschienen in:
Tumor Biology
|
Ausgabe 1/2016
Einloggen, um Zugang zu erhalten
Abstract
Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen. Treatment using rituximab in combination with chemotherapy has dramatically improved overall survival rate of diffuse large B cell lymphoma (DLBCL). Since rituximab can deplete both lymphoma B cells and normal B cells, how rituximab-treatment affects normal B cell function in DLBCL patients under remission is unclear. Here, we examined peripheral blood B cell composition and antigen-specific B cell responses in DLBCL patients in remission and observed reductions in the frequencies of total B cell as well as several major B cell subsets, including CD19+IgD+ naive B cells, CD19+IgD−CD27+ memory B cells, and CD19loCD27hi plasmablasts. Moreover, tetanus toxin (TT)-specific B cell proliferation was reduced in DLBCL patients in remission. On the other hand, HA-specific IgG-secreting B cell responses could be stimulated by influenza vaccination in DLBCL patients in remission, demonstrating that the machinery for generating de novo adaptive B cell responses was functional in DLBCL patients in remission. Our results provided insights in normal B cell function in DLBCL patients in remission.